<html><body> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation of technical requirements for registration of pharmaceuticals for human 
use   ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>  stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>:  photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of  new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> q1b   current step 4 version dated 6 november 1996         this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> has been developed by the appropriate ich expert <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> group and has been subject to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span> by the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties, in accordance with the ich process.  at step 4 of the process the final draft is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for adoption to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/665"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/909"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4054"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4060">european</a></span></a></span></a></span> union</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1524">japan</a></span> and usa.  q1b <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> history  first codification history date new codification november 2005 q1b <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 2 and release for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">public</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>. 28 november 1995 q1b current step 4 version q1b <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 4 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommendation</a></span> for adoption to the three ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies. 6 november 1996 q1b             2 stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>:  photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of  new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> having reached step 4 of the ich process at the ich steering committee meeting  on 6 november 1996, this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for adoption  to the three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties to ich table of contents  1. general......................................................................................................................1 a. preamble.............................................................................................................1 b. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> sources......................................................................................................2 c. procedure............................................................................................................2 2. drug substance.......................................................................................................4 a. presentation of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span>.....................................................................................4 b. analysis of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span>............................................................................................5 c. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1537">judgement</a></span> of results.........................................................................................5 3. drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>...........................................................................................................5 a. presentation of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span>.....................................................................................6 b. analysis of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span>............................................................................................6 c. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1537">judgement</a></span> of results.........................................................................................6 4. annex.........................................................................................................................7 a. quinine chemical actinometry.........................................................................7 5. glossary.....................................................................................................................8 6. references................................................................................................................8   i  stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>: photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>  1. general the ich harmonized tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> covering the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (hereafter referred to as the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>) notes that <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be an integral part of stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>.  this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> is an annex to the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> and addresses the recommendations for photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>. a. preamble the intrinsic photostability characteristics of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> should be evaluated to demonstrate that, as appropriate, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> exposure does not result in unacceptable change.  normally, photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> is carried out on a 
single batch of material selected as described under selection of batches in the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>.  under some circumstances these studies should be repeated if certain 
variations and changes are made to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> (e.g., formulation, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span>).  whether these studies should be repeated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depends</a></span> on the photostability 
characteristics determined at the time of initial filing and the type of variation and/or change made.  the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> primarily addresses the generation of photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> for submission in registration applications for new molecular entities and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2944">associated</a></span> drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> does not cover the photostability of drugs after <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8542">administration</a></span> (i.e. under conditions of use) and those applications not covered by the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>.  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> approaches may be used if they are scientifically sound and justification is provided.  a systematic approach to photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> covering, as appropriate, studies such as: i) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> on the drug substance;  ii) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> on the exposed drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> outside of the immediate pack;  and if necessary ;  iii) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> on the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> in the immediate pack;  and if necessary ;  iv) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> on the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span> pack.  the extent of drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessing</a></span> whether or not acceptable change has occurred at the end of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> exposure <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> as described in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span> flow chart for photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>.  acceptable change is change within limits justified by the applicant.  the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeling</a></span> requirements for photolabile drug substances and drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">established</a></span> by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2033"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2034"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3521">national</a></span></a></span></a></span>/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">regional</a></span></a></span> requirements. 1 photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> b. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> sources the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> sources described below may be used for photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>. the applicant should either maintain an appropriate control of temperature to minimize the effect of localized temperature changes or include a dark control in the same environment unless otherwise justified.  for both options 1 and 2, a pharmaceutical manufacturer/applicant may rely on the spectral distribution specification of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> source manufacturer. option 1 any <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> source that is designed to produce an output similar to the d65/id65 emission <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standard</a></span> such as an artificial daylight fluorescent lamp combining visible 
and ultraviolet (uv) outputs, xenon, or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1882">metal</a></span> halide lamp.  d65 is the internationally recognized <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standard</a></span> for outdoor daylight as defined in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1510">iso</a></span> 10977 (1993).  id65 is the equivalent indoor indirect daylight <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standard</a></span>. for a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> source emitting significant radiation below 320 nm, an appropriate filter(s) may be fitted to eliminate such 
radiation.  option 2 for option 2 the same <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> should be exposed to both the cool white fluorescent and near ultraviolet lamp.  1. a cool white fluorescent lamp designed to produce an output similar to that specified in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1510">iso</a></span> 10977(1993) ; and 2. a near uv fluorescent lamp having a spectral distribution from 320 nm to 400 nm with a maximum energy emission between 350 nm and 370 nm; a significant 
proportion of uv should be in both bands of 320 to 360 nm and 360 to 400 nm.  c. procedure for confirmatory studies, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> should be exposed to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> providing an overall 
illumination of not less than 1.2 million lux hours and an integrated near ultraviolet 
energy of not less than 200 watt hours/square meter to allow <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">direct</a></span> comparisons to be made between the drug substance and drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>.  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> may be exposed side-by-side with a validated chemical actinometric system to ensure the specified <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> exposure is obtained, or for the appropriate duration of time when conditions have been monitored using calibrated radiometers/lux meters.  
an example of an actinometric procedure is provided in the annex.  if protected <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> (e.g., wrapped in aluminum foil) are used as dark controls to 
evaluate the contribution of thermally induced change to the total <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> change, these should be placed alongside the authentic <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span>.   2photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span> flow chart for photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>          start                                         yes          formulation  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">directly</a></span> exposed     change?                                                  yes         acceptable        no    change?                                 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> end         no       immediate yes          pack   immediate pack      change?                                                  yes         acceptable        no    change?                                 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> end         no       <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span>            pack   <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span> pack      change?                                                  yes         acceptable            change?                                 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> end         no                           redesign <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">package</a></span>          or reformulation                      3photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 2. drug substance for drug substances, photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should consist of two parts: forced degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> and confirmatory <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>. the purpose of forced degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> studies is to evaluate the overall photosensitivity of the material for method development purposes and/or degradation pathway elucidation.  this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> may involve the drug substance alone and/or in 
simple solutions/suspensions to validate the analytical procedures.  in these studies, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> should be in chemically inert and transparent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span>.  in these forced 
degradation studies, a variety of exposure conditions may be used, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depending</a></span> on the photosensitivity of the drug substance involved and the intensity of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> sources used.  for development and validation purposes it is appropriate to limit exposure and end the studies if extensive decomposition occurs.  for photostable materials, 
studies may be terminated after an appropriate exposure level has been used.  the 
design of these experiments is left to the applicant™s discretion although the exposure levels used should be justified. under forcing conditions, decomposition <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> may be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> that are unlikely to be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formed</a></span> under the conditions used for confirmatory studies.  this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> 
may be useful in developing and validating suitable analytical methods. if in practice it has been demonstrated they are not <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formed</a></span> in the confirmatory studies, these 
degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> need not be further <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/925">examined</a></span>.  confirmatory studies should then be undertaken to provide the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> necessary for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3629">handling</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span>, and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeling</a></span> (see <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> i.c., procedure, and ii.a., presentation, for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> on the design of these studies).  normally, only one batch of drug substance is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> during the development phase, 
and then the photostability characteristics should be confirmed on a single batch selected as described in the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> if the drug is clearly photostable or 
photolabile.  if the results of the confirmatory study are equivocal, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of up to two additional batches should be conducted.  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> should be selected as described in the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>.  a. presentation of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> care should be taken to ensure that the physical characteristics of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> under <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> are taken into <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> and efforts should be made, such as cooling and/or placing the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1870"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6406">sealed</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span>, to ensure that the effects of the changes in physical 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states</a></span> such as sublimation, evaporation or melting are minimized.  all such precautions should be chosen to provide minimal <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1436">interference</a></span> with the exposure of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> under <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span>.  possible <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interactions</a></span> between the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> and any material used for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> or for general <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2844">protection</a></span> of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span>, should also be considered and eliminated wherever not relevant to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> being carried out.  as a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">direct</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8458">challenge</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> of solid drug substances, an appropriate amount of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> should be taken and placed in a suitable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4676">glass</a></span> or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1837">plastic</a></span> dish and protected 
with a suitable transparent cover if considered necessary.  solid drug substances should be spread across the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> to give a thickness of typically not more than 3 millimeters.  drug substances that are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1672">liquids</a></span> should be exposed in chemically inert and transparent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span>.   4photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> b. analysis of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> at the end of the exposure period, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/925">examined</a></span> for any changes in physical properties (e.g., appearance, clarity, or color of solution) and for assay and degradants by a method suitably validated for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> likely to arise from 
photochemical degradation processes.  where solid drug substance <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> are involved, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sampling</a></span> should ensure that a representative portion is used in individual <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span>.  similar <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sampling</a></span> considerations, 
such as homogenization of the entire <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span>, apply to other materials that may not be homogeneous after exposure.  the analysis of the exposed <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> should be 
performed concomitantly with that of any protected <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> used as dark controls if these are used in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span>.  c. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1537">judgement</a></span> of results the forced degradation studies should be designed to provide suitable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> to 
develop and validate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> methods for the confirmatory studies.  these <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> methods should be capable of resolving and detecting photolytic degradants that appear during the confirmatory studies.  when evaluating the results of these studies, it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1309">important</a></span> to recognize that they <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> part of the stress <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> and are not therefore designed to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> qualitative or quantitative limits for change.  the confirmatory studies should identify precautionary measures needed in manufacturing or in formulation of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, and if <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> resistant <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> is needed.  when evaluating the results of confirmatory studies to determine whether change due to exposure to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> is acceptable, it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1309">important</a></span> to consider the results from other <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability studies in order to assure that the drug will be within justified limits at time of use (see the relevant ich stability and impurity 
guidelines).  3. drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> normally, the studies on drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> should be carried out in a sequential <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5281">manner</a></span> 
starting with <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> the fully exposed <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> then progressing as necessary to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> in the immediate pack and then in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span> pack.  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should 
progress until the results demonstrate that the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is adequately protected from exposure to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span>.  the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> should be exposed to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> conditions described under the procedure in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> i.c.  normally, only one batch of drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> during the development phase, and then the photostability characteristics should be confirmed on a single batch selected as described in the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> if the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> is clearly photostable or 
photolabile.  if the results of the confirmatory study are equivocal, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of up to two additional batches should be conducted.  for some <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> where it has been demonstrated that the immediate pack is 
completely impenetrable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span>, such as <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1446">aluminium</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4575">tubes</a></span> or cans, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should normally only be conducted on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">directly</a></span> exposed drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>.  it may be appropriate to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> certain <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> such as infusion <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1672">liquids</a></span>, dermal <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/301">creams</a></span>, etc., to support their photostability in-use.  the extent of this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depend</a></span> 
on and relate to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">directions</a></span> for use, and is left to the applicant™s discretion.  the analytical procedures used should be suitably validated.   5photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> a. presentation of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> care should be taken to ensure that the physical characteristics of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> under <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> are taken into <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> and efforts, such as cooling and/or placing the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1870"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6406">sealed</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span>, should be made to ensure that the effects of the changes in physical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states</a></span> are minimized, such as sublimation, evaporation, or melting.  all such precautions should be chosen to provide a minimal <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1436">interference</a></span> with the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4085">irradiation</a></span> of 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> under <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span>.  possible <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interactions</a></span> between the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> and any material used for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> or for general <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2844">protection</a></span> of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> should also be considered and eliminated wherever not relevant to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> being carried out.  where practicable when <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> outside of the primary pack, these should be presented in a way similar to the conditions mentioned for the 
drug substance.  the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> should be positioned to provide maximum area of 
exposure to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> source.  for example, tablets, capsules, etc., should be spread in a single layer.  if <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">direct</a></span> exposure is not practical (e.g., due to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2213">oxidation</a></span> of a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>), the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> should be placed in a suitable protective inert transparent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> (e.g., quartz).  if <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> in the immediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> or as <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketed</a></span></a></span> is needed, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> should be placed horizontally or transversely with respect to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> source, whichever provides for the most uniform exposure of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span>.  some adjustment of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> conditions may have to be made when <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> large volume <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">containers</a></span> (e.g., dispensing packs).  b. analysis of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> at the end of the exposure period, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/925">examined</a></span> for any changes in 
physical properties (e.g., appearance, clarity or color of solution, dissolution/disintegration for dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span> such as capsules, etc.) and for assay and degradants by a method suitably validated for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> likely to arise from 
photochemical degradation processes.  when powder <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> are involved, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sampling</a></span> should ensure that a representative portion is used in individual <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span>.   for solid oral dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> should be conducted on an appropriately sized <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3122">composite</a></span> of, for example, 20 tablets or capsules. similar <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sampling</a></span> considerations, such as homogenization or solubilization of 
the entire <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span>, apply to other materials that may not be homogeneous after exposure (e.g., <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/301">creams</a></span>, ointments, suspensions, etc.).  the analysis of the exposed 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> should be performed concomitantly with that of any protected <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> used as dark controls if these are used in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span>.  c. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1537">judgement</a></span> of results <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depending</a></span> on the extent of change special <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeling</a></span> or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> may be needed to mitigate exposure to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span>.  when evaluating the results of photostability studies to determine whether change due to exposure to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> is acceptable, it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1309">important</a></span> to consider the results obtained from other <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability studies in order to assure that the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> will be within proposed specifications during the shelf life (see the relevant ich stability and impurity guidelines).   6photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 4. annex a. quinine chemical actinometry the following provides details of an actinometric procedure for monitoring exposure to a near uv fluorescent lamp (based on fda/<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2033"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2034"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3521">national</a></span></a></span></a></span> institute of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standards</a></span> and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4415">technology</a></span> study).  for other <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> sources/actinometric systems, the same approach may be used, but each actinometric system should be calibrated for the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> source used.  prepare a sufficient quantity of a 2 per cent weight/volume aqueous solution of quinine monohydrochloride dihydrate (if necessary, dissolve by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5503">heating</a></span>).  option 1 put 10 milliliters (ml) of the solution into a 20 ml colorless ampoule <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1870"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6406">seal</a></span></a></span> it hermetically, and use this as the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span>.  separately, put 10 ml of the solution into a 
20 ml colourless ampoule (see note 1), <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1870"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6406">seal</a></span></a></span> it hermetically, wrap in aluminum foil to 
protect completely from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span>, and use this as the control.  expose the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> and control to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> source for an appropriate number of hours.  after exposure determine the absorbances of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> (at) and the control (ao) at 400 nm using a 1 centimeter (cm) path length.  calculate the change in absorbance,  a = at - ao. the length of exposure should be sufficient to ensure a change in absorbance of at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> 0.9. option 2 fill a 1 cm quartz cell and use this as the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span>.  separately fill a 1 cm quartz cell, wrap in aluminum foil to protect completely from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span>, and use this as the control.  expose the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> and control to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> source for an appropriate number of hours.  after exposure determine the absorbances of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> (at) and the control (ao) at 400 nm.  calculate the change in absorbance,  a = at - ao. the length of exposure should be sufficient to ensure a change in absorbance of at <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> 0.5.  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> configurations may be used if appropriately validated.  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> validated chemical actinometers may be used.  note 1: shape and dimensions (see <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1524">japanese</a></span> industry <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standard</a></span> (jis) r3512 (1974) for ampoule specifications)     7photostability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> 5. glossary immediate (primary) pack is that constituent of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> that is in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">direct</a></span> contact with the drug substance or drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, and includes any appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span>.  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/13"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1786">marketing</a></span></a></span> pack is the combination of immediate pack and other secondary <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> such as a carton.  forced degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> studies are those undertaken to degrade the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> deliberately.  these studies, which may be undertaken in the development phase normally on the drug substances, are used to evaluate the overall photosensitivity of 
the material for method development purposes and/or degradation pathway elucidation.  confirmatory studies are those undertaken to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span> photostability characteristics under <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standardized</a></span> conditions.  these studies are used to identify precautionary measures needed in manufacturing or formulation and whether <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span> resistant <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span> and/or special <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeling</a></span> is needed to mitigate exposure to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span>. for the confirmatory studies, the batch(es) should be selected according to batch selection for long-term and accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testings</a></span> which is described in the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>.  6. references quinine actinometry as a method for calibrating ultraviolet radiation intensity in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/626">light</a></span>-stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of pharmaceuticals.  yoshioka s. et al., drug development and industrial pharmacy, 20 (13), 2049 - 2062 
(1994).   8</body><html>